Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

NPF and Global Kinetics Corporation Announce the Commencement of a Clinical Trial to Study Impact of Personal KinetiGraph Use in Routine Clinical Care of Patients with Parkinson's Disease

A multi-center, randomized controlled trial to assess whether the use of continuous objective measurement of changes in mobility in patients with Parkinson’s disease can improve physician treatment decisions and patient outcomes.

Melbourne, Australia & Miami, FL — Global Kinetics Corporation, developer of the Personal KinetiGraph™ (PKG™) mobile health technology for the management of patients with Parkinson’s disease and other movement disorders, and the National Parkinson Foundation (NPF) today announced a clinical research collaboration to study the impact of continuous objective measurement of movement in patients with Parkinson’s disease using the Personal KinetiGraph™ (PKG™) Movement Recording System.

Developed by Global Kinetics, the PKG™ System provides a precise, objective assessment of changes in mobility in patients with diseases and conditions that affect motor skills. The PKG™ is a wrist-worn device that automatically records motion data over a period of 6 days. Physicians can download detailed information about the patient’s symptoms within minutes, identifying changes and trends that can be important considerations in the diagnosis and treatment of Parkinson’s disease. The device can also alert patients when it’s time to take medication as prescribed and the patient can acknowledge medication taken using the device.    

This clinical research project will be a multi-center randomized controlled trial involving over 400 Parkinson’s patients conducted as part of the NPF Parkinson’s Outcomes Project Registry Study which began in 2009 as a core element of the NPF Quality Improvement Initiative. The study has grown to become an unprecedented research collaboration among over 20 leading movement disorder specialist centers and is now the largest clinical study of Parkinson’s disease with nearly 9,000 patients enrolled across four countries. “Our goal with the Parkinson’s Outcomes Project is to identify clinical practices that make a difference in patient outcomes.  The hope is that this new PKG™ study will show how we can use technology to provide information to guide better and more effective clinical decisions, helping more people with Parkinson’s to achieve the best outcomes they can, and that we will be able to translate this into other care settings,” said Peter Schmidt, PhD, NPF Senior Vice President and Chief Mission Officer.

“We are pleased that NPF have recognized the PKG as an essential tool in the management of Parkinson’s and are pleased to be able to partner with them on this clinical trial. One of the great challenges in clinical care of people living with Parkinson’s disease is the subjective nature of symptom observation, which can lead to wide variability in use of medicines and in treatment protocols,” said Global Kinetics Corporation co-founder and Chief Scientific Officer, Professor and neurologist Malcolm Horne. “The PKG™ provides continuous, precise, and accurate assessments of changes in mobility in patients with Parkinson’s disease, which can play an important role in helping make informed treatment decisions, this allows clinicians to provide optimum treatment and ultimately leads to better outcomes for people with Parkinson’s.”

According to data from the NPF Parkinson’s Outcomes Project thus far, there is currently wide variability in the use of different medicines and treatment plans in Parkinson’s disease. In planning for patient care, physicians typically rely on clinical evaluation, a patient’s self-reporting of symptoms[i] and response to medication to guide therapy, potentially increasing the risk of inconsistent and diverse outcomes. “Some Parkinson’s patients are thriving, while others are not. Our goal is to determine what makes that difference. By including the PKG™ System as an element of routine care, this study will enable us to consider the interplay of continuous objective measures of patient mobility among the other factors that ultimately produce different results in different people, and likely paths toward better outcomes. Our goal is not only to optimize today’s care of Parkinson’s patients, but also to help guide tomorrow’s,” said Dr. Schmidt.

“The PKG™ System was FDA cleared in the U.S. in 2014, and many leading clinicians now have extensive experience with this technology, making this an ideal time to initiate this important clinical study,” Professor Horne said.  “This is one of several post-marketing studies currently underway with the PKG™ that will provide a wealth of new data highlighting the role that objective assessment of symptoms can play in improving patient care in Parkinson’s disease in the years ahead.”

About Parkinson’s Disease
Parkinson’s disease (PD) is a chronic, progressive movement disorder that affects the lives of at least one-half million patients in the United States[ii]. The main motor (or movement) related symptoms of Parkinson’s disease are bradykinesia (slowness of movement), rigidity, tremors and postural instability. [iii] Other non-movement symptoms include speech and swallowing difficulties, cognitive impairment, depression or other emotional changes. As the disease progresses, symptoms may interfere with daily activities. Parkinson’s disease can be difficult to diagnose and currently there is no cure. [iv] However, a variety of medications and surgery can help ease the symptoms for some patients.[v]  

About Global Kinetics Corporation
Global Kinetics Corporation is committed to improving the lives of those with Parkinson’s disease and other movement disorders with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph™ (PKG™). Developed by neurologists at the world-renowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, the Personal KinetiGraph™ enables the precise monitoring, quantification and reporting of movement symptoms of neurological diseases. Global Kinetics Corporation, a privately held company, is headquartered in Melbourne, Australia. For more information visit:


[i] NINDS Parkinson's Disease Information Page: What is the prognosis? National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

[ii] Parkinson's Disease Research Web Overview, National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

[iii] NINDS Parkinson's Disease Information Page, National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

[iv] NINDS Parkinson's Disease Information Page: What is the prognosis? National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

[v] NINDS Parkinson's Disease Information Page: What is the prognosis? National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

Wednesday, June 22, 2016
Parkinson's Foundation Study Finds Gender Disparities in Caregiving, with Women at a Disadvantage
Monday, December 4, 2017

Largest Clinical Study Tracking Parkinson’s Patients Over Time Shows Women with Parkinson’s Have Fewer Caregiving Resources than Men with Parkinson’s

Parkinson’s Foundation Invests $60,000 to Develop Innovative Models of Patient Engagement
Wednesday, November 29, 2017

Six Awards Foster Patient-Driven Parkinson’s Research

Jesse Jackson Diagnosed with Parkinson's Disease
Friday, November 17, 2017

Rev. Jesse Jackson’s announcement today that he has been living with Parkinson’s Disease since 2015 further proves that receiving a diagnosis of Parkinson's is not a death sentence. There are many ways that people living with Parkinson's can control the symptoms of the disease with exercise and physical therapy to help maintain mobility and balance.

Update on Tozadenant Trial for Parkinson’s
Thursday, November 16, 2017

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.

Parkinson’s Foundation Adds Marcia Mondavi Borger to Board of Directors
Tuesday, November 14, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Marcia Mondavi Borger to its Board of Directors.

Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger
Thursday, October 26, 2017

Parkinson’s Foundation Establishes ‘Dr. Melvin Yahr Research Award’ to Fund Neurology Fellows, Promote Leadership Diversity in Parkinson’s Research

Parkinson’s Foundation Welcomes Two New Board Members
Tuesday, October 24, 2017

Peter Goldman and Joshua Raskin Join Board of Directors

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Chicago entrepreneur Peter Goldman and New York financial analyst Joshua Raskin to its Board of Directors.

Parkinson's Foundation Unveils New Brand and Website
Thursday, October 19, 2017

NEW YORK and MIAMI /PRNewswire-USNewswire/ — The Parkinson's Foundation today announced the launch of its new brand and website following the recent merger of two legacy organizations – National Parkinson Foundation and Parkinson's Disease Foundation – as part of its mission to

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia
Friday, August 25, 2017

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

Parkinson’s Foundation Announces $1.2 Million Investment to Advance Careers, Support Innovation of Early Career Parkinson’s Scientists
Tuesday, August 8, 2017

NEW YORK & MIAMI The Parkinson's Foundation is pleased to announce a $1.2 million investment in 27 career development and fellowship grants to support the work of promising early career scientists in the field of Parkinson's.


mail icon

Subscribe to get the latest news on treatments, research and other updates.